Your browser doesn't support javascript.
loading
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton.
Afiliação
  • Verma S; Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, ON, Canada. Electronic address: subodh.verma@unityhealth.to.
  • Dhingra NK; Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Butler J; Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
  • Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
  • Ferreira JP; Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative- Cardiovascular and Re
  • Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
  • Januzzi JL; Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
  • Lam CSP; National Heart Centre Singapore, Duke- National University of Singapore Medical School, Singapore.
  • Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Peil B; Boehringer Ingelheim Pharma, Ingelheim, Germany.
  • Nordaby M; Boehringer Ingelheim International, Ingelheim, Germany.
  • Brueckmann M; Boehringer Ingelheim International, Ingelheim, Germany; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
  • Pocock SJ; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
  • Zannad F; Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative- Cardiovascular and Re
  • Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA; Imperial College London, London, UK.
Lancet Diabetes Endocrinol ; 10(1): 35-45, 2022 01.
Article em En | MEDLINE | ID: mdl-34861154
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca / Hipotensão Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2022 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca / Hipotensão Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2022 Tipo de documento: Article País de publicação: Reino Unido